Four-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary Stent in Acute Myocardial Infarction Treated With BallOON Angioplasty)

Christian Spaulding*, Emmanuel Teiger, Philippe Commeau, Olivier Varenne, Ezio Bramucci, Michel Slama, Keavin Beatt, Ashok Tirouvanziam, Lech Polonski, Pieter R. Stella, Richard Clugston, Jean Fajadet, Xavier de Boisgelin, Christophe Bode, Didier Carrie, Andrejs Erglis, Bela Merkely, Stefan Hosten, Ana Cebrian, Patrick WangHans-Peter Stoll, Patrick Henry

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

98 Citations (Scopus)


Objectives The aim of this study was to assess the long-term safety and efficacy of the CYPHER (Cordis, Johnson and Johnson, Bridgewater, New Jersey) sirolimus-eluting coronary stent (SES) in percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

Background Concern over the safety of drug-eluting stents implanted during PCI for STEMI remains, and long-term follow-up from randomized trials are necessary. TYPHOON (Trial to assess the use of the cYPHer sirolimus-eluting stent in acute myocardial infarction treated with ballOON angioplasty) randomized 712 patients with STEMI treated by primary PCI to receive either SES (n = 355) or bare-metal stents (BMS) (n = 357). The primary end point, target vessel failure at 1 year, was significantly lower in the SES group than in the BMS group (7.3% vs. 14.3%, p = 0.004) with no increase in adverse events.

Methods A 4-year follow-up was performed. Complete data were available in 501 patients (70%), and the survival status is known in 580 patients (81%).

Results Freedom from target lesion revascularization (TLR) at 4 years was significantly better in the SES group (92.4% vs. 85.1%; p = 0.002); there were no significant differences in freedom from cardiac death (97.6% and 95.9%; p = 0.37) or freedom from repeat myocardial infarction (94.8% and 95.6%; p = 0.85) between the SES and BMS groups. No difference in definite/probable stent thrombosis was noted at 4 years (SES: 4.4%, BMS: 4.8%, p = 0.83). In the 580 patients with known survival status at 4 years, the all-cause death rate was 5.8% in the SES and 7.0% in the BMS group (p = 0.61).

Conclusions In the 70% of patients with complete follow-up at 4 years, SES demonstrated sustained efficacy to reduce TLR with no difference in death, repeat myocardial infarction or stent thrombosis. (The Study to Assess AMI Treated With Balloon Angioplasty [TYPHOON]; NCT00232830) (J Am Coll Cardiol Intv 2011;4: 14-23) (C) 2011 by the American College of Cardiology Foundation

Original languageEnglish
Pages (from-to)14-23
Number of pages10
JournalJacc-Cardiovascular interventions
Issue number1
Publication statusPublished - Jan-2011


  • bare-metal stent
  • percutaneous coronary intervention
  • sirolimus-eluting coronary stent
  • target lesion revascularization

Cite this